The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...
Mature data in patients with a minimum follow-up of 22 months (N=21) shows excellent results, well above historical controls ...
In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...
Summit Therapeutics and its Chinese partner Akeso have a few competitors now.
Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...
Within the PD-(L)1 class, Keytruda is responsible for over 55% of the total global sales. Its current revenue total makes ...
Keytruda is currently indicated in a variety of cancers, including classical Hodgkin lymphoma, primary mediastinal large ...
BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback